clinical trial · NCT06821334
A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)
Merck Sharp & Dohme LLC·phase1·completed·n = 37
HealthyMK-6194Placebo
brief summary
The goal of this study is to learn how safe MK-6194 is in healthy Chinese adults and how well people tolerate it.
started
Apr 23, 2024
primary completion
Aug 9, 2024
completion
Aug 9, 2024
last updated
Feb 12, 2025
official title
A Randomized, Double-Blind, Placebo-Controlled Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics of MK-6194 in Healthy Chinese Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol